{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.14 vs. cons $2.10",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$911M vs. cons $904.8M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA margin (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~27.0% vs. cons 26.75%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$2.18 vs. cons $2.19 (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.53 vs. cons $8.48 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.5% vs. cons 3.5% (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.6,
  "day5_path": "FADE",
  "day5_rationale": "The Q2 EPS beat and modest FY2026 raise support the initial reaction, but Q3 guidance of ~$2.18 versus $2.19 consensus limits upward revisions; the out-period math leaves little incremental FY2026 estimate upside after absorbing the Q2 beat.",
  "day5_confidence": "LOW"
}